- ￥380
- Solarbio
- 北京
- II01401
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Stroe at -20℃，6 months.
- 保质期：
Stroe at -20℃，6 months.
- 英文名：
Irinotecan(10mM in DMSO,Sterile）
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
97682-44-5
- 规格：
1ml
| 基本信息 | |
| CAS | No.97682-44-5 |
| 中文名称 | 伊立替康(10mM in DMSO,无菌） |
| 英文名称 | Irinotecan(10mM in DMSO,Sterile） |
| 分子式 | C33H38N4O6 |
| 分子量 | 586.68 |
| 溶解性 | 请根据自己的实验要求使用。 |
| 外观(性状) | 无菌溶液 |
| 储存条件 | Stroe at -20℃，6 months. |
| 靶点 | Topoisomerase |
| 通路 | DNA Damage/DNA Repair |
| 背景说明 | Irinotecan是拓扑异构酶I抑制剂，通过与拓扑异构酶I-DNA复合物结合来防止DNA链的再连接。 |
| 生物活性 | Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor， preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.[1-5] |
| In Vitro | Irinotecan is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells， with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM， respectively， and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC)， with an IC50 of 1.3 μM[3]. |
| 细胞实验 | Irinotecan (CPT-11， 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days， on two consecutive weeks in rats， and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However， Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11， 100-300 mg/kg， i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%， respectively， and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3]. |
| 细胞实验 | Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20，000 for LoVo cells， 100，000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells， 40 h for HT-29 cells). After washing with 0.15 M NaCl， the cells are further grown for two doubling times in normal medium， detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2]. |
| 动物实验 | Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution， for a doses of 5 mg/kg daily for 5 days， on two consecutive weeks， followed by a 7-days rest period， referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1]. |
| 数据来源文献 | [1]. Morales C， et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [2]. Pavillard V， et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [3]. Allegrini G， et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. [4]. Dela Cruz FS， et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. [5]. Huang MY， et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21(2):130-42. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
II01401 伊立替康(10mM in DMSO,无菌） 抑制剂/拮抗剂/激动剂 索莱宝
￥380
